# Ezetimibe (Zetia / Ezetrol) *Also known as: Zetia, Ezetrol* In bodybuilding discussions, ezetimibe enters the conversation when cholesterol results worsen on TRT or a cycle—or stay high despite being lean and active. The attraction is lowering LDL and ApoB without simply pushing a statin dose higher. Users compare it alone and alongside a statin, with muscle soreness and follow-up bloodwork high on the list of concerns. Educational information only — not medical advice. Modelled values are not individual measurements or dosing recommendations. ## Dosage & duration U.S. ZETIA label: lipid-lowering treatment ### Labeled daily dose **Product label** - **Dose:** 10 mg - **How often:** Once daily, with or without food - **How long:** Ongoing treatment; review the lipid response When combined with a statin or another lipid medicine, that product’s instructions and risks also apply. - [DailyMed — ZETIA prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb) — Sections 1–2, 5, 7, 12.1–12.3 and 14: LDL lowering, 10 mg daily with or without food, follow-up lipids from 4 weeks; muscle/liver risks and interactions. Parent and active glucuronide differ; both recirculate. This is chronic lipid treatment rather than a fixed bodybuilding cycle. Bile-acid sequestrants require label-specified separation; review other medicines with the prescriber. Dose-context sources checked: 2026-10-09. ## At a glance - **Bodybuilding goal:** Improve LDL and ApoB Sources or review notes: [1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb). - **Main comparison:** Alone or with a statin? Sources or review notes: [1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb). - **Training concern:** Muscle symptoms and tolerance Sources or review notes: [1](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb). **Catalog evidence label (not clinical review):** Human RCT evidence ## Ezetimibe alone or with a statin? | Question | Ezetimibe alone | With a statin | | --- | --- | --- | | Goal | LDL lowering without a statin | Additional LDL lowering | | Approach | Less cholesterol absorbed in the intestine | Two cholesterol-lowering pathways | | Follow-up | Lipid response and tolerability | Combined response; muscle and liver concerns | Better LDL results do not address every cardiovascular effect of PED use. Visual sources checked: 2026-10-09. - [DailyMed — ZETIA prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb) — Sections 1–2, 5, 7, 12.1–12.3 and 14: LDL lowering, 10 mg daily with or without food, follow-up lipids from 4 weeks; muscle/liver risks and interactions. Parent and active glucuronide differ; both recirculate. ## Overview ## Why do lifters look at ezetimibe? The practical motivation is usually to improve a lipid panel without disrupting training. The discussions reviewed include people using TRT or AAS, people worried about statin-related soreness, and lean lifters whose cholesterol remains high despite diet and cardio. Ezetimibe is appealing because it offers a different route to lowering LDL. ## Ezetimibe alone or a statin combination? It reduces cholesterol absorption in the intestine. A statin combination can add further LDL lowering, which is why some users compare adding ezetimibe with increasing their statin. Reported experiences vary; the decision is better judged by the actual lipid change and tolerability than by which drug sounds “milder.” ## What about low HDL? Users also ask whether it will repair a low HDL result after a cycle. Its established role is reducing LDL and related lipid markers; do not assume it will normalize the whole panel. Keep the individual results visible rather than treating a better total-cholesterol number as a complete answer. ## How do you tell whether it is helping? The ZETIA label allows LDL assessment as early as 4 weeks after starting. Feeling no different in the gym does not mean the lipid effect is absent. Conversely, unexplained soreness or weakness deserves review rather than being dismissed as ordinary training fatigue. Liver tests and other medicines matter too, especially in combination treatment. ## Relative timing model Relative timing curve **Output:** Ezetimibe (Zetia / Ezetrol): relative timing (relative units). Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength. A simplified relative timing curve; it does not predict LDL cholesterol or combined parent/metabolite concentrations. ### Timing assumptions and scale Uses parent-ezetimibe timing from the fasted 10 mg Ezetrol arm in Sun 2023: 19.38 h terminal half-life and 5 h median peak. Absorption rate is inferred, not directly measured. One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales. - **Timing half-life used:** 19.38 hours - **Absorption half-life assumed:** 1.155962 hours - **Reference amount for the relative scale:** 1 mg - A first-order absorption half-life of 1.15596 h reproduces the selected 5 h peak with the study terminal rate. - Enterohepatic recycling and the active glucuronide metabolite are not represented; a smooth single peak is a simplification. - A single fixed 1 mg input peaks at 1 relative unit. This normalization is not a blood concentration or potency comparison. - Linear dose scaling and repeated-dose addition illustrate a timing scenario; they are not validated estimates of total ezetimibe exposure or LDL response. - An absolute one-compartment fit to the parent peak and timing would give AUC∞ 116.35 ng·h/mL versus the study 68.62 (+69.6%); its blood-level amplitude was therefore not adopted. ### Model sources - [Sun et al. 2023 — ezetimibe/Ezetrol bioequivalence study](https://pmc.ncbi.nlm.nih.gov/articles/PMC9896679/) — Table 1, fasted Ezetrol 10 mg reference arm: parent Cmax 3.48 ng/mL, median Tmax 5 h, mean half-life 19.38 h, AUC∞ 68.62 ng·h/mL. Total ezetimibe and glucuronide are separate analytes. DOI 10.1186/s40360-023-00649-y. - [DailyMed — ZETIA prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb) — Sections 1–2, 5, 7, 12.1–12.3 and 14: LDL lowering, 10 mg daily with or without food, follow-up lipids from 4 weeks; muscle/liver risks and interactions. Parent and active glucuronide differ; both recirculate. - [Patrick et al. 2002 — human ezetimibe disposition](https://pubmed.ncbi.nlm.nih.gov/11901097/) — Original study abstract: eight healthy men after 20 mg radiolabeled oral ezetimibe; unconjugated and conjugated concentration profiles had multiple peaks, supporting enterohepatic recirculation. **Revision:** ezetimibe-parent-timing-2026-10 · version 1 ## Sources and review notes Summary source check: 2026-10-09; see source notes 1. This does not certify medical review of the whole page. ### Notes on the quick facts - **Bodybuilding goal:** The aim is better lipid results while managing the broader effects of TRT or AAS use. Source check: 2026-10-09; not a medical review. - **Main comparison:** Ezetimibe can add LDL lowering through a different cholesterol pathway. Source check: 2026-10-09; not a medical review. - **Training concern:** Users hope for a treatment they tolerate well; ezetimibe is not automatically free of muscle side effects. Source check: 2026-10-09; not a medical review. ### References 1. [DailyMed — ZETIA prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=174e45e0-45bb-48b7-9e60-8f6cfc1d22bb) — Sections 1–2, 5, 7, 12.1–12.3 and 14: LDL lowering, 10 mg daily with or without food, follow-up lipids from 4 weeks; muscle/liver risks and interactions. Parent and active glucuronide differ; both recirculate. 2. [Sun et al. 2023 — ezetimibe/Ezetrol bioequivalence study](https://pmc.ncbi.nlm.nih.gov/articles/PMC9896679/) — Table 1, fasted Ezetrol 10 mg reference arm: parent Cmax 3.48 ng/mL, median Tmax 5 h, mean half-life 19.38 h, AUC∞ 68.62 ng·h/mL. Total ezetimibe and glucuronide are separate analytes. DOI 10.1186/s40360-023-00649-y. 3. [Patrick et al. 2002 — human ezetimibe disposition](https://pubmed.ncbi.nlm.nih.gov/11901097/) — Original study abstract: eight healthy men after 20 mg radiolabeled oral ezetimibe; unconjugated and conjugated concentration profiles had multiple peaks, supporting enterohepatic recirculation. --- **Canonical URL:** https://anabolicplotter.com/compounds/ezetimibe/ **Methodology:** https://anabolicplotter.com/methodology/ **Plot:** https://anabolicplotter.com/plot?compound=ezetimibe